Pfizer has been a big name in healthcare for decades, but it has been a largely underwhelming investment over the past 10 ...

It isn't a bad business model, but the U.S. market is largely saturated. Competition is fierce, and more and more ways to buy medication now exist, exacerbating the issue. They include grocery stores, ...

Retail Gazette takes a closer look at Boots' new private equity owner and what the deal means for the future of the health ...

For CVS, Q2 earnings will be a critical inflection point. A miss could trigger a breakup or further decline, making the stock ...

Recent stock price pullbacks present buying opportunities for long-term investors, despite no obvious negative news. Read ...

Why it matters: As Walgreens works toward finalizing its private equity deal with Sycamore Partners, which was announced in March, it is showing nice improvement in its US retail pharmacy unit.

Walgreens Boots Alliance continues to see weakness in U.S. front-end sales, says Chief Executive Tim Wentworth Shares of Walgreens Boots Alliance Inc. were gaining ground in early Thursday trading ...

In the most recent trading session, Walgreens Boots Alliance (WBA) closed at $11.18, indicating a +0.45% shift from the previous trading day.

Shares of Walgreens Boots Alliance Inc. WBA advanced 1.60% to $11.40 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 3.26% ...

Earnings Results Walgreens’ U.S. retail sales remain weak, but here’s why the stock is rising Walgreens Boots Alliance continues to see weakness in U.S. front-end sales, says Chief Executive ...